Back to Search
Start Over
Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study
- Source :
- Human Reproduction. 19:1979-1984
- Publication Year :
- 2004
- Publisher :
- Oxford University Press (OUP), 2004.
-
Abstract
- BACKGROUND: When administered in the late follicular phase to prevent an LH surge, GnRH antagonists induce a sharp decrease in serum LH levels that may be detrimental for assisted reproductive technology cycle outcome. Therefore, a prospective study was designed to assess the effects of recombinant human (r)LH supplementation during GnRH antagonist (cetrorelix) administration. METHODS: The protocol consisted of cycle programming with oral contraceptive pill, ovarian stimulation with rFSH and flexible administration of a single dose of cetrorelix (3 mg). A total of 218 patients from three IVF centres were randomized (by sealed envelops or according to woman's birth date) to receive (n = 114) or not (n = 104) a daily injection of rLH 75 IU from GnRH antagonist initiation to hCG injection. RESULTS: The only significant difference was a higher serum peak E 2 level in patients treated with rLH (1476 ± 787 versus 1012 ± 659 pg/ml, P < 0.001) whereas the numbers of oocytes and embryos as well as the delivery rate (25.2 versus 24%) and the implantation rate per embryo (19.1 versus 17.4%) were similar in both groups. CONCLUSIONS: These results show that in an unselected group of patients, there is no evident benefit to supplement GnRH antagonist-treated cycles with rLH.
- Subjects :
- Adult
medicine.medical_specialty
Oral contraceptive pill
medicine.drug_class
medicine.medical_treatment
Cell Count
Fertilization in Vitro
Gonadotropin-releasing hormone
Gonadotropin-releasing hormone antagonist
Gonadotropin-Releasing Hormone
Andrology
Hormone Antagonists
Internal medicine
Follicular phase
Humans
Medicine
Embryo Implantation
Prospective Studies
Sperm Injections, Intracytoplasmic
Prospective cohort study
Assisted reproductive technology
Estradiol
business.industry
Rehabilitation
Antagonist
Obstetrics and Gynecology
Luteinizing Hormone
Delivery, Obstetric
Embryo, Mammalian
Recombinant Proteins
Treatment Outcome
Endocrinology
Reproductive Medicine
Oocytes
Female
business
Luteinizing hormone
Subjects
Details
- ISSN :
- 14602350
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Human Reproduction
- Accession number :
- edsair.doi.dedup.....5777f70aa086a15d47c1a45dbbf5eaf2